Intellipharmaceutics (IPCI) Time to Buy

[Biotechmaster]

CEO says multiple deals, FDA approvals and more filings are in the works

Thursday, 21 April 2011 01:02


As we first told our premium subscribers on Tuesday, the management team at Intellipharmaceutics (Nasdaq:IPCI )(TSX:I) is clearly excited about the progress they've been making. The pharmaceutical company specializies in the reformulation and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs and they are finally on the verge of going commercial in a big way. With multiple pending FDA approvals, we first profiled IPCI in detail in late January. The company caught our attention for several reasons. Among them is the fact that the reported sales for branded and generic versions of their pending approval products stands at close to $9 billion.

IPCI develops both ANDA (Abbreviated New Drug Application) product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway. Their CEO, Dr. Isa Odidi, is easily considered one of the sector's top drug delivery innovators. When Odidi was at Biovail- which merged with Valeant Pharmaceuticals International (NYSE: VRX)(TSX:VRX) in 2010, he was performing drug alchemy with formulations that mimicked several hard-to-manufacture generic versions of expensive drugs- among them, Pfizer